Posts tagged “GSK”
British-based drugmaker GlaxoSmithKline (NYSE: GSK) posted a loss of $616 million for the fourth quarter of 2015 - compared with a profit of over $1 for the same period a year earlier- as the company moved to integrate new businesses. Its top exec says GSK is making progress.
GlaxoSmithKline, which is under growing investor pressure to improve its financials, is investing alongside Johnson & Johnson in another startup fund. For the second time in a week, GSK moves to back new and emerging ventures in hopes of driving future growth.
In today's Bulldog wrapup of technology and life science news: Sprint is cutting jobs and closing six call centers; another security problem for Lenovo; investor pressure mounts for change at GSK; and Arista counter-sues Cisco.
In today's Bulldog wrapup of technology and life science news: Lenovo fights lawsuits over adware; Google pays back taxes in U.K.; GSK puts $15 million in new university drug development fund; and Novozymes launches a poultry product with French partner.
A woman who is a twin sister of a former scientists at GSK is charged conspiracy to steal secrets from the drug giant. The sister, who was fired recently by GSK, also is charged along with three others.
New GSK drug's price criticized; Google expands in Tennessee; 'Dotcom' faces extradition; Turing seeks CEO
In today's Bulldog wrapup of technology and life science news: An independent group is criticizing the price of GSK's new asthma drug; Google to invfest $600 million in Tennessee data center expansion; Kim Dotcom faces extradition to the U.S.; and drug company Turing is looking for a new CEO to replace Martin Shkreli.
GlaxoSmithKline is boosting its own efforts to fight AIDS by agreeing to buy the HIV drug pipeline of Bristol-Myers Squibb in a deal valued at as much as $1.46 billion. In May, GSK said it would invest $20 million in a deal with UNC-Chapel Hill to develop an AIDS cure.
GSK arthritis drug advances; Washington sues tech support firm; streaming music fees go up; FDA OKs cheaper diabetes drug
In today's Bulldog wrapup of technology and life science news: A new arthritis drug from GSK moves toward regulatory approval; the state of Washington is suing tech support firm iYogi, alleging it scams customers; streaming music fees are going up; and the FDA approves a cheaper diabetes drug.
GSK's $440M antibody deal; INC shareholders sell; Bioventus, PowerSecure make buys; Dara BioSciences merger advances
In today's wrapup of technology and life science news: GSK strikes investment deal for antibodies; INC's big shareholders sell; Bioventus and PowerSecure make acquisitions; and Dara Biosciences moves ahead with merger.
GSK has struck a development agreement with Idera Pharmaceuticals, Inc., which develops drugs for patients with renal disease. The deal comes with an up-front payment of $2.5 million to Idera, and is worth as much as $100 million.
GSK today announced the ten Triangle-area nonprofits that will receive $40,000 each to build healthy communities by tackling employment, housing, literacy, and other pressing community health challenges.
GlaxoSmithKline, one of the Research Triangle's largest employers, saw increased sales in the third quarter that beat analysts estimates in the thrid quarter despite declining profits. It reported sales of $9.4 billion in the quarter, up 11 percent over the same period last year, but profits declined to $2.6 billion, a 5 percent drop.
A closely watched study of GlaxoSmithKline plc's Breo Ellipta respiratory treatment failed to prove that it extends patients' lives, denying the drugmaker a much-needed marketing edge in its most lucrative - but declining - medicine category.
GlaxoSmithKline has struck another major deal with Novartis. This time the drug giants are teaming up for a deal worth more than $1 billion plus royalties to GSK for an experimental multiple sclerosis drug. The deal will help GSK focus on other priorities, a top executive says.
Bezos disputes critical Amazon story; GSK plant reopens; Lenovo's new storage move; report links AT&T, NSA
In today's Bulldog wrapup of technology and life science news: Jeff Bezos disputes a New York Times story critical of the company's work environment; GSK reopens its plant in Zebulon; Lenovo launches a new storage product; and a New York Times report links AT&T with the NSA.
- An early rally in stocks is mostly gone by the closing bell
- Yellen: Persistent economic weakness could slow rate hikes
- Obama vows to press ahead on Clean Power Plan after setback
- Thought leaders gather in Raleigh to create Internet of Things roadmap
- Forecast: Retail sales to grow 3.1 percent in 2016